This event has ended. Visit the official site or create your own event on Sched.
Back To Schedule
Thursday, November 2 • 10:30 - 12:00
107 – Canada's Clinical Innovation in Fifty Years: The Future May Be Rare/ L’innovation clinique du Canada dans cinquante ans : Les possibilités d’avenir peuvent être rares
Panel Organizer: Angela Behboodi, Hoffmann-La Roche Limited

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Panel Organizer: Angela Behboodi, Hoffmann-La Roche Limited

Canada has long been a strong contributor to the world’s advances in clinical research and health innovation. Harnessing many unique assets that span demographic diversity, to academic leadership, clinical expertise, government commitment and public-private collaboration; sustaining Canada’s role as a medical research and health innovation hub is paramount and particularly apparent when examining support for rare disease. As the rate of scientific advancement accelerates, public policy, clinical practice, and health-system adoption have not kept pace and the need for adaptive policy, novel implementation and infrastructure accommodation widens. This gap is only amplified when you consider the “extraordinary” needs of people living with a rare disorder. However, there are areas where great strides have been made and solutions to address these shared challenges have been realized, both here in Canada and across the globe. This panel will surface challenges, opportunities and emerging best practices in enabling a sustained, vibrant Canadian science and health innovation environment for orphan and common diseases.
The panel “Canada’s Clinical Innovation in Fifty Years: The Future May Be Rare” focuses on the future of clinical innovation as a means to cultivate supportive conditions for improved care for rare patients in Canada. The use of scientific knowledge to improve patient impact and system receptivity is at the core of this topic.  More importantly, it raises numerous interesting and difficult policy questions related to how Canada must ready the system to address the “extraordinary” needs of rare patients including; novel clinical innovation strategies, new regulatory and funding mechanisms, infrastructure accommodation and knowledge sharing across boundaries and through centres of excellence.  

avatar for Dr. Lawrence Korngut

Dr. Lawrence Korngut

Associate Professor, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary
Dr. Korngut is a neurologist and clinical neurophysiologist at the Calgary Neuromuscular Clinic and is the Director of the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the... Read More →

avatar for Dr. Kym Boycott

Dr. Kym Boycott

Leader, Care4Rare Canada and Rare Diseases Models and Mechanisms networks
Kym Boycott is a Medical Geneticist at the Children’s Hospital of Eastern Ontario (CHEO), Senior Scientist at the CHEO Research Institute, and Professor of Pediatrics at the University of Ottawa. Dr. Boycott’s research program in rare diseases bridges clinical medicine to basic... Read More →
avatar for Susan Marlin

Susan Marlin

CEO, Clinical Trials Ontario
As the CEO of Clinical Trials Ontario, Susan Marlin is dedicated to ensuring a robust environment remains for scientific discovery in Ontario and Canada. She has been actively engaged in research ethics for many years and serves on many Boards supporting clinical research including... Read More →
avatar for Dr. William McKellin

Dr. William McKellin

Medical Anthropologist, University of British Columbia
Dr. William McKellin, brings a unique perspective to the panel as a father of a child living with a rare disorder, a founding Board Member of the Rare Disease Foundation of Canada and a Medical Anthropologist at UBC who studies “translational research” and “functional endpoints... Read More →
avatar for Dr. Durhane Wong-Rieger

Dr. Durhane Wong-Rieger

CEO, Canadian Organization for Rare Disorders
Dr. Durhane Wong-Rieger, PhD., the CEO of Canadian Organization for Rare Disorders is acknowledged both in Canada and globally for advancing the agenda on rare disease and spurring public discourse on the merits of clinical research. She is leading the charge on implementation of... Read More →

Thursday November 2, 2017 10:30 - 12:00 EDT
ROOM 211 Shaw Centre, 55 Colonel By Dr, Ottawa, ON K1N 9J2